Comment on 'Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis'.
作者信息
Zhao Jingwen, Xu Qiang
机构信息
Tianjin University of Traditional Chinese Medicine.
Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine.
出版信息
Int J Surg. 2024 Sep 1;110(9):5895-5896. doi: 10.1097/JS9.0000000000001657.
Abstract
摘要
相似文献
1
Comment on 'Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis'.
Int J Surg. 2024 Sep 1;110(9):5895-5896. doi: 10.1097/JS9.0000000000001657.
2
Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis.
Int J Surg. 2024 Jun 1;110(6):3923-3936. doi: 10.1097/JS9.0000000000001372.
3
Cell-free Tumor DNA: a Promising Technology for Diagnosis, Surveillance and Therapeutic Decision in Urothelial Carcinoma of the Bladder.
Curr Oncol Rep. 2025 Mar;27(3):225-235. doi: 10.1007/s11912-025-01648-4. Epub 2025 Feb 12.
4
Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer.
JCO Precis Oncol. 2025 Jan;9:e2400472. doi: 10.1200/PO-24-00472. Epub 2025 Jan 6.
5
Prognostic and predictive value of pre-treatment blood-based inflammatory biomarkers in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Front Immunol. 2025 Mar 17;16:1554048. doi: 10.3389/fimmu.2025.1554048. eCollection 2025.
6
C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis.
Crit Rev Oncol Hematol. 2024 May;197:104352. doi: 10.1016/j.critrevonc.2024.104352. Epub 2024 Apr 16.
7
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.
Nat Med. 2024 Sep;30(9):2508-2516. doi: 10.1038/s41591-024-03091-7. Epub 2024 Jun 1.
8
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Cancer. 2018 May 15;124(10):2115-2124. doi: 10.1002/cncr.31314. Epub 2018 Mar 8.
9
Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma.
Am Soc Clin Oncol Educ Book. 2025 Jan;45(2):e471912. doi: 10.1200/EDBK-25-471912. Epub 2025 Jan 30.
10
Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
J Urol. 2021 Oct;206(4):873-884. doi: 10.1097/JU.0000000000001878. Epub 2021 Jun 1.
本文引用的文献
1
Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis.
Int J Surg. 2024 Jun 1;110(6):3923-3936. doi: 10.1097/JS9.0000000000001372.
2
Association between plasma circulating tumor DNA and the prognosis of esophageal cancer patients: a meta-analysis.
Int J Surg. 2024 Jul 1;110(7):4370-4381. doi: 10.1097/JS9.0000000000001373.
3
Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma.
Cancer Sci. 2024 Feb;115(2):529-539. doi: 10.1111/cas.16025. Epub 2023 Dec 11.
4
Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application.
Mol Cancer. 2023 Feb 21;22(1):37. doi: 10.1186/s12943-023-01745-7.
5
Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies.
Clin Transl Med. 2020 Dec;10(8):e254. doi: 10.1002/ctm2.254.
Zotero 插件